Pipeline — registered trials by phase
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
— · Multifocal Motor Neuropathy · Active Not Recruiting · est. 2028-12-31
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
— · Myasthenia Gravis · Recruiting · est. 2034-06
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
— · Myasthenia Gravis, MG, gMG · Recruiting · est. 2028-03-07
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
— · Chronic Inflammatory Demyelinating Polyneuropathy · Completed · est. 2026-02-19
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
— · Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy · Recruiting · est. 2033-01
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
— · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) · Recruiting · est. 2029-10
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
— · Congenital Myasthenic Syndrome · Recruiting · est. 2027-06
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
— · Generalized Myasthenia Gravis (gMG), gMG · Recruiting · est. 2027-11
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
— · New Onset Generalized Myasthenia Gravis (gMG) · Recruiting · est. 2026-08
Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects
— · Healthy Volunteers · Completed · est. 2019-09-26
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
— · Healthy Volunteers · Completed · est. 2016-11-15
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
— · Cancer · Completed · est. 2018-04-25
A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults
— · Bioequivalence · Completed · est. 2023-05-12
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants
— · Healthy Volunteer, Healthy Adult Participants · Recruiting · est. 2026-09-18
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants
— · Healthy Volunteers (HV), Healthy Volunteer · Recruiting · est. 2026-12
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
— · Healthy Volunteers · Completed · est. 2026-03-20
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
— · Healthy Volunteers · Recruiting · est. 2026-12-31
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
— · Healthy Volunteers · Completed · est. 2022-03-08
SAD and MAD Study With IV and SC Doses of ARGX-117
— · Healthy Volunteers · Completed · est. 2022-08-26
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
— · Cancer · Completed · est. 2017-03
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
— · Healthy Volunteers · Completed · est. 2020-12-24
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
— · Bioavailability Study · Completed · est. 2018-09-19
A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
— · Multifocal Motor Neuropathy (MMN) · Recruiting · est. 2028-02-01
A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants
— · Healthy Volunteers · Completed · est. 2024-08-08
A Study to Assess the Safety of ARGX-109 in Healthy Volunteers
— · Healthy Volunteer · Completed · est. 2025-08-08
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
— · Congenital Myasthenic Syndrome, CMS · Active Not Recruiting · est. 2027-08-24
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
— · Healthy Volunteers · Recruiting · est. 2027-03
A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod
— · Renal Impairment · Completed · est. 2024-06-12
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
— · Autoimmune Encephalitis (AE) · Not Yet Recruiting · est. 2030-07
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
— · Antibody-mediated Rejection · Active Not Recruiting · est. 2027-11
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
— · Dermatomyositis, Myositis · Active Not Recruiting · est. 2026-11
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
— · Postural Orthostatic Tachycardia Syndrome · Completed · est. 2024-04-18
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)
— · Lupus Nephritis · Completed · est. 2025-07-02
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
— · Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensory Neuropathies · Not Yet Recruiting · est. 2028-07-28
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
— · Systemic Sclerosis (SSc) · Recruiting · est. 2027-02
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
— · Multifocal Motor Neuropathy · Completed · est. 2024-06-04
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
— · Multifocal Motor Neuropathy (MMN) · Active Not Recruiting · est. 2029-09-30
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
— · Myasthenia Gravis · Completed · est. 2017-10-20
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
— · Guillain-Barré Syndrome (GBS) · Not Yet Recruiting · est. 2028-01
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
— · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Active Not Recruiting · est. 2027-04-30
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
— · Primary Immune Thrombocytopenia · Completed · est. 2019-04-09
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
— · Primary Sjögren's Syndrome · Completed · est. 2024-01-29
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
— · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis · Recruiting · est. 2027-10
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
— · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG · Recruiting · est. 2028-03-07
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
— · Spinal Muscular Atrophy (SMA) · Recruiting · est. 2029-05-28
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
— · Pemphigus Vulgaris, Pemphigus Foliaceus · Completed · est. 2020-10-28
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
— · Delayed Graft Function · Active Not Recruiting · est. 2025-10-16
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
— · Immunoglobulin A Nephropathy (IgAN) · Not Yet Recruiting · est. 2029-10-29
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
— · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Completed · est. 2023-05-11
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
— · Primary Sjögren's Syndrome · Completed · est. 2025-02-03
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis · Completed · est. 2024-12-31
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
— · Bullous Pemphigoid · Completed · est. 2024-09-13
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
— · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), CIDP · Not Yet Recruiting · est. 2028-04
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
— · Congenital Myasthenic Syndrome, CMS · Not Yet Recruiting · est. 2030-10
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
— · Graves Disease · Recruiting · est. 2028-06
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
— · Myasthenia Gravis, Ocular · Active Not Recruiting · est. 2026-01-12
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
— · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy · Recruiting · est. 2027-10-07
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
— · Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis · Enrolling By Invitation · est. 2028-09
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
— · Primary Immune Thrombocytopenia · Completed · est. 2022-02-03
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
— · Primary Immune Thrombocytopenia (ITP) · Recruiting · est. 2028-06
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
— · Graves' Disease, Graves Disease · Recruiting · est. 2028-06
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
— · Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP · Recruiting · est. 2028-10
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized · Active Not Recruiting · est. 2025-06-30
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
— · Generalized Myasthenia Gravis · Completed · est. 2020-04-06
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
— · Primary Immune Thrombocytopenia · Completed · est. 2026-03-11
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis, gMG · Enrolling By Invitation · est. 2029-09
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
— · Pemphigus Vulgaris, Pemphigus Foliaceus · Completed · est. 2023-08-22
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis · Recruiting · est. 2027-03
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
— · Multifocal Motor Neuropathy (MMN), MMN · Active Not Recruiting · est. 2026-09
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
— · Primary Immune Thrombocytopenia · Completed · est. 2023-10-09
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
— · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy · Recruiting · est. 2027-09
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG · Completed · est. 2023-08-24
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
— · Primary Sjogrens Disease · Active Not Recruiting · est. 2027-07
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
— · Primary Immune Thrombocytopenia · Active Not Recruiting · est. 2026-10-01
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis · Completed · est. 2021-11-02
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where argenx is lead sponsor; 78 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 6-K2026-10-08Report of foreign issuer
- 6-K2026-09-29Report of foreign issuer
- 6-K2026-08-27Report of foreign issuer
- SC TO-T/A2026-08-27SC TO-T/A
- SC TO-T/A2026-08-19SC TO-T/A
- 6-K2026-08-17Report of foreign issuer
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SC TO-T/A2026-08-06SC TO-T/A
- SC TO-T2026-08-06SC TO-T
- 6-K2026-08-03Report of foreign issuer
- SC TO-C2026-07-28SC TO-C
- SC TO-C2026-07-27SC TO-C
- 6-K2026-07-27Report of foreign issuer
- 6-K2026-07-23Report of foreign issuer
- 6-K2026-06-23Report of foreign issuer
- 6-K2026-06-03Report of foreign issuer
- 6-K2026-05-11Report of foreign issuer
- 6-K2026-05-07Report of foreign issuer
- 6-K2026-05-06Report of foreign issuer
- SCHEDULE 13G/A2026-05-06SCHEDULE 13G/A
- 6-K2026-04-20Report of foreign issuer
- 6-K2026-03-20Report of foreign issuer
- 20-F2026-03-19Annual report (foreign)
- 6-K2026-03-19Report of foreign issuer
- 6-K2026-03-06Report of foreign issuer
- 6-K2026-02-26Report of foreign issuer
- 6-K2026-02-26Report of foreign issuer
- 6-K2026-01-13Report of foreign issuer
- 6-K2026-01-12Report of foreign issuer
- 6-K2026-01-05Report of foreign issuer
- UPLOAD2025-12-18UPLOAD
- S-82025-12-17Employee stock plan
- 6-K2025-12-15Report of foreign issuer
- 6-K2025-11-18Report of foreign issuer
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- 6-K2025-10-30Report of foreign issuer
- 6-K2025-10-29Report of foreign issuer
- 6-K2025-10-15Report of foreign issuer
- 6-K2025-10-03Report of foreign issuer
- CORRESP2025-09-25CORRESP
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.